Sending time2021-01-30 13:29
comment
[앵커]
The European Union has officially approved the COVID-19 vaccine jointly developed by AstraZeneca and Oxford University in the UK.
The number of vaccines that can be inoculated has increased to three, but when supply was disrupted due to a shortage of supplies, the European Union actually introduced restrictions on exports from overseas.
PD Bang Joo-hee delivers.
[리포터]
The European Union and the European Commission’s executive committee officially approved the COVID-19 vaccine jointly developed by the multinational pharmaceutical company AstraZeneca and the University of Oxford in the UK.
It is the third COVID-19 vaccine approved by the EU for conditional use following the vaccine developed by Pfizer-Bioentech and Modena.
The challenge is securing vaccine supplies.
When AstraZeneca was notified that it could deliver only 40% of the 80 million shipments it decided to supply in the first quarter, the EU demanded to supply a vaccine produced in the UK, raising the conflict between the two sides.
U.S. pharmaceutical company Modena vaccines are also disrupting supply.
Moderna has decided to cut France’s supply for next month by 25% from plan, and has also informed Italy that it will cut supply by 20%.
Vaccination disruptions in the European Union are intensifying, such as extending the interval between the first and second vaccinations or temporarily suspending vaccinations due to a lack of vaccine supplies.
The EU Commission has implemented a system that requires pharmaceutical companies to obtain approval from member states when exporting COVID-19 vaccines produced in the EU outside the region.
Pharmaceutical companies need to inform the member country where the factory is located in advance of the new export target and quantity, but if the specified criteria are not met, the member country may block the export of vaccines.
The World Health Organization has expressed concern over the move to restrict exports, saying that vaccines should be shared fairly by all countries.
<테워드로스 아드하놈 거브러여수스 / WHO 사무총장> “Vaccine nationalism may help political goals in the short term, but it will ultimately lead to shortsighted and self-defeating consequences.”
Bloomberg News also noted that the EU’s move is at risk of being criticized for protectionism.
This is Joo-hee Bang on Yonhap News TV.
Yonhap News TV article inquiries and reports: katok/line jebo23
Unauthorized reproduction-redistribution prohibited>
2021/01/30 13:29 sent